Mesenchymal stem cells in tissue repair

Amy M Dimarino, Arnold I Caplan, Tracey L Bonfield, Amy M Dimarino, Arnold I Caplan, Tracey L Bonfield

Abstract

The advent of mesenchymal stem cell (MSC)-based therapies for clinical therapeutics has been an exciting and new innovation for the treatment of a variety of diseases associated with inflammation, tissue damage, and subsequent regeneration and repair. Application-based ability to measure MSC potency and fate of the cells post-MSC therapy are the variables that confound the use of MSCs therapeutics in human diseases. An evaluation of MSC function and applications with attention to detail in the preparation as well as quality control and quality assurance are only as good as the assays that are developed. In vivo measures of efficacy and potency require an appreciation of the overall pathophysiology of the model and standardization of outcome measures. The new concepts of how MSC's participate in the tissue regeneration and wound repair process and further, how this is impacted by estimates of efficacy and potency are important new topics. In this regard, this chapter will review some of the in vitro and in vivo assays for MSC function and activity and their application to the clinical arena.

Keywords: adult mesenchymal stem cells; anti-inflammatory agents; antimicrobial protein; milieu therapy; regenerative pharmacology.

Figures

Figure 1
Figure 1
The dynamic definition of MSC efficacy. Efficacy or the biological impact of MSC on biological processes is dependent on a variety of parameter. As outlined in the schematic below the variability in efficacy is dependent not only on the source and quality of the MSCs themselves but also on the response of the recipient to the administration of MSCs. This is a dynamic and continuous process that can ultimately be defined by the potency of the MSCs in the context of disease, model, and outcome measure.
Figure 2
Figure 2
The mesengenic process. Mesenchymal stem cells are multipotent and possess the ability to proliferate and commit to different cell types based on the environmental conditions. They also may be redirected from one lineage to another.

References

    1. Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol (2009) 217:318–2410.1002/path.2469
    1. Tian H, Wu DP, Chen GH. Current research advance on abnormalities of mesenchymal stem cells in hematological malignancies. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2011) 19:1319–24
    1. Patel SA, Sherman L, Munoz J, Rameshwar P. Immunological properties of mesenchymal stem cells and clinical implications. Arch Immunol Ther Exp (Warsz) (2008) 56:1–810.1007/s00005-008-0001-x
    1. Matthay MA. Advances and challenges in translating stem cell therapies for clinical diseases. Transl Res (2010) 156:107–1110.1016/j.trsl.2010.07.007
    1. Cook MM, Futrega K, Osiecki M, Kabiri M, Kul B, Rice A, et al. Micromarrows? 3D co-culture of haematopoietic stem cells and mesenchymal stromal cells. Tissue Eng Part C Methods (2012) 18:319–2810.1089/ten.TEC.2011.0159
    1. Bonfield TL, Nolan Koloze MT, Lennon DP, Caplan AI. Defining human mesenchymal stem cell efficacy in vivo. J Inflamm (Lond) (2010) 7:51.10.1186/1476-9255-7-51
    1. Tian Y, Deng YB, Huang YJ, Wang Y. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation. Immunol Invest (2008) 37:29–4210.1080/08820130701410223
    1. Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L, et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant (2010) 16:838–4710.1016/j.bbmt.2010.01.011
    1. Bobis S, Jarocha D, Majka M. Mesenchymal stem cells: characteristics and clinical applications. Folia Histochem Cytobiol (2006) 44:215–30
    1. Brooke G, Rossetti T, Ilic N, Murray P, Hancock S, Pelekanos R, et al. Points to consider in designing mesenchymal stem cell-based clinical trials. Transfus Med Hemother (2008) 35:279–8510.1159/000143158
    1. Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med (2007) 262:509–2510.1111/j.1365-2796.2007.01844.x
    1. Dennis JE, Caplan AI. Differentiation potential of conditionally immortalized mesenchymal progenitor cells from adult marrow of a H-2Kb-tsA58 transgenic mouse. J Cell Physiol (1996) 167:523–3810.1002/(SICI)1097-4652(199606)167:3<523::AID-JCP16>;2-E
    1. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 8:315–710.1080/14653240600855905
    1. Dennis JE, Merriam A, Awadallah A, Yoo JU, Johnstone B, Caplan AI. A quadripotential mesenchymal progenitor cell isolated from the marrow of an adult mouse. J Bone Miner Res (1999) 14:700–910.1359/jbmr.1999.14.5.700
    1. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood (2005) 105:2214–910.1182/blood-2004-07-2921
    1. Jarvinen L, Badri L, Wettlaufer S, Ohtsuka T, Standiford TJ, Toews GB, et al. Lung resident mesenchymal stem cells isolated from human lung allografts inhibit T cell proliferation via a soluble mediator. J Immunol (2008) 181:4389–96
    1. Bonfield TL, Caplan AI. Adult mesenchymal stem cells: an innovative therapeutic for lung diseases. Discov Med (2010) 9:337–45
    1. Caplan AI. All MSCs are pericytes? Cell Stem Cell (2008) 3:229–3010.1016/j.stem.2008.08.008
    1. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell (2008) 3:301–1310.1016/j.stem.2008.07.003
    1. Solchaga LA, Welter JF, Lennon DP, Caplan AI. Generation of pluripotent stem cells and their differentiation to the chondrocytic phenotype. Methods Mol Med (2004) 100:53–68
    1. Solchaga LA, Penick K, Porter JD, Goldberg VM, Caplan AI, Welter JF. FGF-2 enhances the mitotic and chondrogenic potentials of human adult bone marrow-derived mesenchymal stem cells. J Cell Physiol (2005) 203:398–40910.1002/jcp.20238
    1. Solchaga LA, Penick K, Goldberg VM, Caplan AI, Welter JF. Fibroblast growth factor-2 enhances proliferation and delays loss of chondrogenic potential in human adult bone-marrow-derived mesenchymal stem cells. Tissue Eng Part A (2010) 16:1009–1910.1089/ten.TEA.2009.0100
    1. Dominici M, Hofmann TJ, Horwitz EM. Bone marrow mesenchymal cells: biological properties and clinical applications. J Biol Regul Homeost Agents (2001) 15:28–37
    1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science (1999) 284:143–710.1126/science.284.5411.143
    1. Dennis JE, Haynesworth SE, Young RG, Caplan AI. Osteogenesis in marrow-derived mesenchymal cell porous ceramic composites transplanted subcutaneously: effect of fibronectin and laminin on cell retention and rate of osteogenic expression. Cell Transplant (1992) 1:23–32
    1. Dennis JE, Konstantakos EK, Arm D, Caplan AI. In vivo osteogenesis assay: a rapid method for quantitative analysis. Biomaterials (1998) 19:1323–810.1016/S0142-9612(97)00170-1
    1. Dennis JE, Caplan AI. Porous ceramic vehicles for rat-marrow-derived (Rattus norvegicus) osteogenic cell delivery: effects of pre-treatment with fibronectin or laminin. J Oral Implantol (1993) 19:106–15
    1. Haynesworth SE, Baber MA, Caplan AI. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol (1996) 166:585–9210.1002/(SICI)1097-4652(199603)166:3<585::AID-JCP13>;2-7
    1. Bonfield TL, Barna BP, John N, Malur A, Culver DA, Kavuru MS, et al. Suppression of activin A in autoimmune lung disease associated with anti-GM-CSF. J Autoimmun (2006) 26:37–4110.1016/j.jaut.2005.10.004
    1. Rasmusson I, Uhlin M, Le Blanc K, Levitsky V. Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J Leukoc Biol (2007) 82:887–9310.1189/jlb.0307140
    1. Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 65:55–6310.1016/0022-1759(83)90303-4
    1. Abdallah BM, Kassem M. Human mesenchymal stem cells: from basic biology to clinical applications. Gene Ther (2008) 15:109–1610.1038/sj.gt.3303067
    1. Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med (2010) 182:1047–5710.1164/rccm.201001-0010OC
    1. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia (2009) 57:1192–20310.1002/glia.20841
    1. Miller RH, Bai L, Lennon DP, Caplan AI. The potential of mesenchymal stem cells for neural repair. Discov Med (2010) 9:236–42
    1. Miller RH, Bai L. Cellular approaches for stimulating CNS remyelination. Regen Med (2007) 2:817–2910.2217/17460751.2.5.817
    1. Matthay MA, Thompson BT, Read EJ, McKenna DH, Jr, Liu KD, Calfee CS, et al. Therapeutic potential of mesenchymal stem cells for severe acute lung injury. Chest (2010) 138:965–7210.1378/chest.10-0518
    1. Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells (2010) 28:2229–3810.1002/stem.544
    1. Matthay MA, Goolaerts A, Howard JP, Lee JW. Mesenchymal stem cells for acute lung injury: preclinical evidence. Crit Care Med (2010) 38:S569–7310.1097/CCM.0b013e3181f1ff1d
    1. Bosnjak B, Stelzmueller B, Erb KJ, Epstein MM. Treatment of allergic asthma: modulation of Th2 cells and their responses. Respir Res (2011) 12:114.10.1186/1465-9921-12-114
    1. Larghero J, Vija L, Lecourt S, Michel L, Verrecchia F, Farge D. Mesenchymal stem cells and immunomodulation: toward new immunosuppressive strategies for the treatment of autoimmune diseases? Rev Med Interne (2009) 30:287–9910.1016/j.revmed.2008.08.019
    1. Le BK. Mesenchymal stromal cells: tissue repair and immune modulation. Cytotherapy (2006) 8:559–6110.1080/14653240601045399
    1. da Silva ML, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells (2008) 26:2287–9910.1634/stemcells.2007-1122
    1. Arima N, Nakamura F, Fukunaga A, Hirata H, Machida H, Kouno S, et al. Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: a pilot study. Cytotherapy (2010) 12:265–810.3109/14653240903390795
    1. Price MJ, Chou CC, Frantzen M, Miyamoto T, Kar S, Lee S, et al. Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties. Int J Cardiol (2006) 111:231–910.1016/j.ijcard.2005.07.036
    1. Weiss DJ, Berberich MA, Borok Z, Gail DB, Kolls JK, Penland C, et al. Adult stem cells, lung biology, and lung disease. NHLBI/Cystic Fibrosis Foundation Workshop. Proc Am Thorac Soc (2006) 3:193–20710.1513/pats.200601-013MS
    1. Matthay MA. Treatment of acute lung injury: clinical and experimental studies. Proc Am Thorac Soc (2008) 5:297–910.1513/pats.200708-141DR
    1. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem (2006) 98:1076–8410.1002/jcb.20886
    1. Dennis JE, Cohen N, Goldberg VM, Caplan AI. Targeted delivery of progenitor cells for cartilage repair. J Orthop Res (2004) 22:735–4110.1016/j.orthres.2003.12.002
    1. Gharaee-Kermani M, Gyetko MR, Hu B, Phan SH. New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy. Pharm Res (2007) 24:819–4110.1007/s11095-006-9216-x
    1. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med (2005) 11:367–810.1038/nm0405-367
    1. Chamberlain JR, Deyle DR, Schwarze U, Wang P, Hirata RK, Li Y, et al. Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta. Mol Ther (2008) 16:187–9310.1038/sj.mt.6300339
    1. Deyle DR, Khan IF, Ren G, Wang PR, Kho J, Schwarze U, et al. Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs. Mol Ther (2012) 20:204–1310.1038/mt.2011.209
    1. Sackstein R. Glycoengineering of HCELL, the human bone marrow homing receptor: sweetly programming cell migration. Ann Biomed Eng (2012) 40:766–7610.1007/s10439-011-0461-8
    1. Burdick MM, Chu JT, Godar S, Sackstein R. HCELL is the major E- and L-selectin ligand expressed on LS174T colon carcinoma cells. J Biol Chem (2006) 281:13899–90510.1074/jbc.M513617200
    1. Sng J, Lufkin T. Emerging stem cell therapies: treatment, safety, and biology. Stem Cells Int (2012) 23:1383–910.1155/2012/521343
    1. De Ugarte DA, Alfonso Z, Zuk PA, Elbarbary A, Zhu M, Ashjian P, et al. Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow. Immunol Lett (2003) 89:267–7010.1016/S0165-2478(03)00108-1
    1. Choi H, Lee RH, Bazhanov N, Oh JY, Prockop DJ. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages. Blood (2011) 118:330–810.1182/blood-2010-12-327353
    1. Oh JY, Roddy GW, Choi H, Lee RH, Ylostalo JH, Rosa RH, Jr, et al. Anti-inflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injury. Proc Natl Acad Sci U S A (2010) 107:16875–8010.1073/pnas.1012451107
    1. Heldens GT, Davidson EN, Vitters EL, Schreurs BW, Piek E, Berg WB, et al. Catabolic factors and osteoarthritis-conditioned medium inhibit chondrogenesis of human mesenchymal stem cells. Tissue Eng Part A (2012) 18:45–5410.1089/ten.TEA.2011.0083
    1. Wu H, Lu W, Mahato RI. Mesenchymal stem cells as a gene delivery vehicle for successful islet transplantation. Pharm Res (2011) 28:2098–10910.1007/s11095-011-0434-5
    1. Volarevic V, Al-Qahtani A, Arsenijevic N, Pajovic S, Lukic ML. Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. Autoimmunity (2010) 43:255–6310.3109/08916930903305641
    1. Chen K, Wang D, Du WT, Han ZB, Ren H, Chi Y, et al. Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Clin Immunol (2010) 135:448–5810.1016/j.clim.2010.01.015
    1. Yun SP, Ryu JM, Jang MW, Han HJ. Interaction of profilin-1 and F-actin via a beta-arrestin-1/JNK signaling pathway involved in prostaglandin E(2)-induced human mesenchymal stem cells migration and proliferation. J Cell Physiol (2011) 226:559–7110.1002/jcp.22366
    1. Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, Kobayashi N, et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant (2010) 19:667–7910.3727/096368910X508762
    1. Lanz TV, Opitz CA, Ho PP, Agrawal A, Lutz C, Weller M, et al. Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). Stem Cells Dev (2010) 19:657–6810.1089/scd.2009.0385
    1. Tomic S, Djokic J, Vasilijic S, Vucevic D, Todorovic V, Supic G, et al. Immunomodulatory properties of mesenchymal stem cells derived from dental pulp and dental follicle are susceptible to activation by toll-like receptor agonists. Stem Cells Dev (2011) 20:695–70810.1089/scd.2010.0145
    1. Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol (2012) 67:1–810.1111/j.1600-0897.2011.01069.x
    1. Amin AH, Abd Elmageed ZY, Nair D, Partyka MI, Kadowitz PJ, Belmadani S, et al. Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice. Lab Invest (2010) 90:985–9610.1038/labinvest.2010.86
    1. Bonfield TL, Koloze M, Lennon DP, Zuchowski B, Yang SE, Caplan AI. Human mesenchymal stem cells suppress chronic airway inflammation in the murine ovalbumin asthma model. Am J Physiol Lung Cell Mol Physiol (2010) 299:L760–7010.1152/ajplung.00182.2009
    1. Bhakta NR, Woodruff PG. Human asthma phenotypes: from the clinic, to cytokines, and back again. Immunol Rev (2011) 242:220–3210.1111/j.1600-065X.2011.01032.x
    1. Bellone G, Scirelli T, Emanuelli G. Osteo-promoting activity of osteoplant angiostad in vitro. Minerva Stomatol (2008) 57:189–98
    1. Kunzmann S, Wright JR, Steinhilber W, Kramer BW, Blaser K, Speer CP, et al. TGF-beta1 in SP-A preparations influence immune suppressive properties of SP-A on human CD4+ T lymphocytes. Am J Physiol Lung Cell Mol Physiol (2006) 291:L747–5610.1152/ajplung.00401.2005
    1. Kintscher U, Wakino S, Bruemmer D, Goetze S, Graf K, Hsueh WA, et al. TGF-beta(1) induces peroxisome proliferator-activated receptor gamma1 and gamma2 expression in human THP-1 monocytes. Biochem Biophys Res Commun (2002) 297:794–910.1016/S0006-291X(02)02264-7
    1. Liu H, Liu S, Li Y, Wang X, Xue W, Ge G, et al. The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. PLoS ONE (2012) 7:e34608.10.1371/journal.pone.0034608
    1. Liu X, Duan B, Cheng Z, Jia X, Mao L, Fu H, et al. SDF-1/CXCR4 axis modulates bone marrow mesenchymal stem cell apoptosis, migration and cytokine secretion. Protein Cell (2011) 2:845–5410.1007/s13238-011-1097-z
    1. Ma M, Ye JY, Deng R, Dee CM, Chan GC. Mesenchymal stromal cells may enhance metastasis of neuroblastoma via SDF-1/CXCR4 and SDF-1/CXCR7 signaling. Cancer Lett (2011) 312:1–1010.1016/j.canlet.2011.06.028
    1. Schantz JT, Chim H, Whiteman M. Cell guidance in tissue engineering: SDF-1 mediates site-directed homing of mesenchymal stem cells within three-dimensional polycaprolactone scaffolds. Tissue Eng (2007) 13:2615–2410.1089/ten.2006.0438
    1. Jang MW, Yun SP, Park JH, Ryu JM, Lee JH, Han HJ. Cooperation of Epac1/Rap1/Akt and PKA in prostaglandin E(2)-induced proliferation of human umbilical cord blood derived mesenchymal stem cells: involvement of c-Myc and VEGF expression. J Cell Physiol (2012) 227:3756–6710.1002/jcp.24084
    1. Lee SH, Lee YJ, Song CH, Ahn YK, Han HJ. Role of FAK phosphorylation in hypoxia-induced hMSCS migration: involvement of VEGF as well as MAPKS and eNOS pathways. Am J Physiol Cell Physiol (2010) 298:C847–5610.1152/ajpcell.00418.2009
    1. Jeon ES, Heo SC, Lee IH, Choi YJ, Park JH, Choi KU, et al. Ovarian cancer-derived lysophosphatidic acid stimulates secretion of VEGF and stromal cell-derived factor-1 alpha from human mesenchymal stem cells. Exp Mol Med (2010) 42:280–9310.3858/emm.2010.42.4.027
    1. Scott A, Weldon S, Buchanan PJ, Schock B, Ernst RK, McAuley DF, et al. Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo. PLoS ONE (2011) 6:e26525.10.1371/journal.pone.0026525

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel